The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading…
Shares in Novo Nordisk surged 6.9% Tuesday, after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly. The pill’s starting dose of 1.5 milligrams will be…
LONDON — European markets are expected to open in the red, extending losses into a second day after hitting record highs last week. The U.K.’s FTSE 100 is seen almost 0.2% down, France’s CAC is set to be 0.1% below the flatline, and Germany’s DAX is set for a soft open, according to data from…
President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with…
Novo Nordisk CEO Maziar Mike Doustdar shakes hands with U.S. President Donald Trump during an event to announce a deal with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White House in Washington, D.C., U.S., November 6, 2025. Jonathan Ernst |…
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand…